Medicines for Malaria Venture (MMV), a not-for-profit public-private partnership in antimalarial drug research.
MMV was launched in 1999, with initial seed finance of US$4 million from the Government of Switzerland, the Department for International Development (UK), the Government of the Netherlands, The World Bank, and Rockefeller Foundation.
Its mission is to reduce the burden of malaria in disease-endemic countries by developing and facilitating the delivery of antimalarial drugs. Its vision is a world in which these innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate the disease.
MMV and partners manage a portfolio of over 65 projects, the largest portfolio of antimalarial R&D and access projects ever assembled.